The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus.

摘要: Increased antibacterial resistance jeopardizes current therapeutic strategies to control infections, soliciting the development of novel drugs with new mechanisms action. This study reports discovery potent and selective antistaphylococcal activity 3-bromopyruvate (3BP), an antimetabolite in preclinical as anticancer drug. 3BP showed bactericidal against Staphylococcus aureus, active concentrations comparable those reported be effective cancer cells. In contrast, no relevant was observed other ESKAPE bacteria (Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa Enterobacter spp.). The confirmed using a panel human veterinary strains, including multi-drug-resistant isolates. highest under conditions that increase its stability (acidic pH) or promote S. aureus fermentative metabolism (anaerobiosis), although also able kill metabolically inactive synergism gentamicin, disrupted preformed biofilms at only slightly higher than inhibiting planktonic unravels antibiofilm activities for drug 3BP, paving way further studies.